Dr. AbdulRaheem Alshanqiti

Consultant Medical Oncologist; Deputy Executive Director, Oncology Center of Excellence

Dr. Abdulraheem Alshangiti is a distinguished Saudi medical oncologist based in Dammam, widely recognized for his clinical leadership and core specialization in gastrointestinal (GI) and genitourinary (GU) malignancies. He currently serves as the Deputy Executive Director of the Oncology Center of Excellence at King Fahad Specialist Hospital-Dammam (KFSHD).

Current Roles & Leadership
• Executive Leadership: Functions as the Deputy Executive Director of the Oncology Center of Excellence at King Fahad Specialist Hospital-Dammam.
• Department Chair: Serves as the Chairman of Adult Medical Oncology at KFSHD.
• Institutional Governance: Formerly headed the hospital's Scholarship Program and served as the Chairman of the Formulary & Therapeutics Committee.
• Scientific Memberships: Holds active memberships in the Saudi Society of Medical Oncology, Saudi Society of GI Oncology, American Society of Medical Oncology, and European Society of Medical Oncology.

Education & Board Certifications
Dr. Alshangiti possesses elite double-board credentials from top North American medical associations:
• Medical Degree: Earned his Bachelor of Medicine and Surgery (MBBS) from King Saud University in Riyadh.
• Board Certifications: Dually certified by the American Board of Internal Medicine (ABIM) and the Royal College of Physicians and Surgeons of Canada (FRCPC) in both Internal Medicine and Medical Oncology.
• Advanced Fellowships: Completed specialized postgraduate sub-specialty fellowship training tailored entirely to Gastrointestinal and Genitourinary Malignancies.

Genitourinary (GU) Cancer Focus & Research
Dr. Alshangiti is heavily engaged in regional panel discussions, oncology congresses, and clinical strategy mapping regarding the management of GU solid tumors:
• Bladder Cancer Management: Actively contributes to medical guidelines regarding advanced therapeutics, including leading specialized updates on managing Muscle-Invasive Bladder Cancer (MIBC) and sequencing systemic therapies.
• Renal Cell Carcinoma (RCC): Collaborates closely with the Saudi Oncology Society to evaluate and map out optimized first-line targeted treatment combinations and immunotherapies for metastatic kidney cancer.
• Prostate Cancer Pathways: Participates in multi-disciplinary tumor boards to uniform clinical care pathways for advanced and castration-resistant prostate cancer patients in the Eastern Region.